Literature DB >> 1954193

Reduction in the incidence of biliary and other surgical complications of ascariasis according to the decrease of its national egg prevalence in Korea.

J Y Chai1, S Y Cho, S H Lee, B S Seo.   

Abstract

While various examples of rationale or benefits of ascariasis control could justify a necessity of control activity in a community, few practical index other than the egg prevalence or intensity of infection has been used to evaluate the efficacy obtained by the control activity. A literature-based retrospective study was undertaken to provide some numerical data on the decreasing morbidity of surgical ascariasis as a consequence of ascariasis control in Korea. A thorough review of literatures (1959-1990) on biliary and other surgical complications of ascariasis reported from general hospitals revealed that their incidence has been decreasing very proportionally to the national figures of its egg prevalence and worm burden. For example, according to the remarkable decreases of the prevalence of ascariasis, there is an evident decreasing tendency of the proportion (%) of biliary ascariasis cases among all biliary surgical patients and the proportion of biliary ascariasis cases among all biliary stone patients in general hospitals. It is highly suggested that the Korean people have been much benefited by the control activity of ascariasis executed at a national scale since 1960s, especially in terms of incidence of biliary and other surgical complications of ascariasis.

Entities:  

Mesh:

Year:  1991        PMID: 1954193     DOI: 10.3347/kjp.1991.29.2.101

Source DB:  PubMed          Journal:  Kisaengchunghak Chapchi


  2 in total

1.  Identification of parasite DNA in common bile duct stones by PCR and DNA sequencing.

Authors:  Ji Sun Jang; Kyung Ho Kim; Jae Ran Yu; Soo Ung Lee
Journal:  Korean J Parasitol       Date:  2007-12       Impact factor: 1.341

2.  A Case of Biliary Ascariasis in Korea.

Authors:  Jun-Ho Choi; Min Seo
Journal:  Korean J Parasitol       Date:  2017-12-31       Impact factor: 1.341

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.